189 related articles for article (PubMed ID: 22507800)
1. JAK2 inhibitors and their impact in myeloproliferative neoplasms.
Geyer HL; Tibes R; Mesa RA
Hematology; 2012 Apr; 17 Suppl 1():S129-32. PubMed ID: 22507800
[TBL] [Abstract][Full Text] [Related]
2. Targeting myeloproliferative neoplasms with JAK inhibitors.
Pardanani A; Tefferi A
Curr Opin Hematol; 2011 Mar; 18(2):105-10. PubMed ID: 21245760
[TBL] [Abstract][Full Text] [Related]
3. New generation small-molecule inhibitors in myeloproliferative neoplasms.
Passamonti F; Maffioli M; Caramazza D
Curr Opin Hematol; 2012 Mar; 19(2):117-23. PubMed ID: 22227528
[TBL] [Abstract][Full Text] [Related]
4. Current outlook on molecular pathogenesis and treatment of myeloproliferative neoplasms.
Tibes R; Bogenberger JM; Benson KL; Mesa RA
Mol Diagn Ther; 2012 Oct; 16(5):269-83. PubMed ID: 23023734
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic potential of JAK2 inhibitors.
Verstovsek S
Hematology Am Soc Hematol Educ Program; 2009; ():636-42. PubMed ID: 20008249
[TBL] [Abstract][Full Text] [Related]
6. JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations.
Pardanani A; Vannucchi AM; Passamonti F; Cervantes F; Barbui T; Tefferi A
Leukemia; 2011 Feb; 25(2):218-25. PubMed ID: 21079613
[TBL] [Abstract][Full Text] [Related]
7. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms.
Quintás-Cardama A; Vaddi K; Liu P; Manshouri T; Li J; Scherle PA; Caulder E; Wen X; Li Y; Waeltz P; Rupar M; Burn T; Lo Y; Kelley J; Covington M; Shepard S; Rodgers JD; Haley P; Kantarjian H; Fridman JS; Verstovsek S
Blood; 2010 Apr; 115(15):3109-17. PubMed ID: 20130243
[TBL] [Abstract][Full Text] [Related]
8. Novel therapeutics in myeloproliferative neoplasms.
Venugopal S; Mascarenhas J
J Hematol Oncol; 2020 Dec; 13(1):162. PubMed ID: 33267911
[TBL] [Abstract][Full Text] [Related]
9. The role of JAK1/2 inhibitors in the treatment of chronic myeloproliferative neoplasms.
Keohane C; Mesa R; Harrison C
Am Soc Clin Oncol Educ Book; 2013; ():301-5. PubMed ID: 23714529
[TBL] [Abstract][Full Text] [Related]
10. JAK inhibitors: pharmacology and clinical activity in chronic myeloprolipherative neoplasms.
Treliński J; Robak T
Curr Med Chem; 2013; 20(9):1147-61. PubMed ID: 23317159
[TBL] [Abstract][Full Text] [Related]
11. Off-Target Effects of BCR-ABL and JAK2 Inhibitors.
Green MR; Newton MD; Fancher KM
Am J Clin Oncol; 2016 Feb; 39(1):76-84. PubMed ID: 24351780
[TBL] [Abstract][Full Text] [Related]
12. The Next Generation of JAK Inhibitors: an Update on Fedratinib, Momelotonib, and Pacritinib.
Patel AA; Odenike O
Curr Hematol Malig Rep; 2020 Dec; 15(6):409-418. PubMed ID: 32780250
[TBL] [Abstract][Full Text] [Related]
13. Janus kinase inhibitors: an update on the progress and promise of targeted therapy in the myeloproliferative neoplasms.
Stein BL; Crispino JD; Moliterno AR
Curr Opin Oncol; 2011 Nov; 23(6):609-16. PubMed ID: 21993415
[TBL] [Abstract][Full Text] [Related]
14. The role of pacritinib in the management of myelofibrosis.
Duong VH; Komrokji RS
Expert Rev Hematol; 2014 Jun; 7(3):325-32. PubMed ID: 24746271
[TBL] [Abstract][Full Text] [Related]
15. The BCR-ABL1-negative myeloproliferative neoplasms: a review of JAK inhibitors in the therapeutic armamentarium.
Griesshammer M; Sadjadian P
Expert Opin Pharmacother; 2017 Dec; 18(18):1929-1938. PubMed ID: 29134817
[TBL] [Abstract][Full Text] [Related]
16. Comparative phenotypic profiling of the JAK2 inhibitors ruxolitinib, fedratinib, momelotinib, and pacritinib reveals distinct mechanistic signatures.
Singer JW; Al-Fayoumi S; Taylor J; Velichko S; O'Mahony A
PLoS One; 2019; 14(9):e0222944. PubMed ID: 31560729
[TBL] [Abstract][Full Text] [Related]
17. Breakthroughs in myeloproliferative neoplasms.
Santos FP; Verstovsek S
Hematology; 2012 Apr; 17 Suppl 1():S55-8. PubMed ID: 22507780
[TBL] [Abstract][Full Text] [Related]
18. JAK2 inhibitors for myelofibrosis: why are they effective in patients with and without JAK2V617F mutation?
Santos FP; Verstovsek S
Anticancer Agents Med Chem; 2012 Nov; 12(9):1098-109. PubMed ID: 22583424
[TBL] [Abstract][Full Text] [Related]
19. Therapy for myeloproliferative neoplasms: when, which agent, and how?
Geyer HL; Mesa RA
Blood; 2014 Dec; 124(24):3529-37. PubMed ID: 25472969
[TBL] [Abstract][Full Text] [Related]
20. New JAK2 inhibitors for myeloproliferative neoplasms.
Quintás-Cardama A; Verstovsek S
Expert Opin Investig Drugs; 2011 Jul; 20(7):961-72. PubMed ID: 21521147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
